TIDMCBX

RNS Number : 4631C

Cellular Goods PLC

12 June 2023

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014, as retained as part of the law of England and Wales. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Press release

12 June 2023

Cellular Goods PLC

("Cellular Goods" or "the Company")

Correction: Grant of Warrants

The following amendment has been made to the 'Grant of Warrants' announcement released on 9 June 2023 at 07:00 a.m. under RNS number 1766C. The description of the total number of Warrants in issue was incomplete, which has been corrected in the revised text below.

Cellular Goods (LSE: CBX) a UK-based skincare and wellness company providing premium consumer products formulated with lab-produced cannabinoids, announces that it has granted a total of 3,000,000 warrants to subscribe for new ordinary shares of GBP0.001 each ("Warrants") to members of its Advisory Board. The Warrants are exercisable at 1.5 pence per ordinary share.

One third of the warrants will vest on 8 June 2024 with the remaining two thirds vesting in 24 equal monthly instalments thereafter. The Warrants have an exercise period from the date of grant to 8 June 2028.

Following the issue of the Warrants, the Company has a total of:

 
 --   12,500,000 warrants in issue to staff and founders at exercise prices between 5 pence and 
       8.13 pence per ordinary share; 
 --   4,000,000 granted to the Company's non-executive directors at exercise prices between 0.97 
       pence and 2.9 pence per ordinary share; 
 --   5,000,000 at an exercise price of 0.97 pence per ordinary share to Matthew Lodge in connection 
       with the King Tide acquisition; 
 --   3,000,000 to the Advisory Board, details of which are set out in the announcement; and 
 --   12,960,000 to brokers at an exercise price of 5 pence per ordinary share in connection with 
       the Company's IPO.

In addition, under the Company's share option plan, options over in aggregate 24,331,594 ordinary shares at exercise prices between 1.2 pence and 7.812 pence per ordinary share remain exercisable.

For further information please contact:

 
 Cellular Goods 
 Darcy Taylor                          via Tancredi +44 207 887 7633 
  Chairman and interim CEO 
  Neil Thapar                           +44 787 645 5323 
  Investor Relations 
                                      ------------------------------ 
 First Sentinel Corporate Finance 
                                      ------------------------------ 
 Corporate Broker & Advisor 
  Brian Stockbridge                      +44 7876 888 011 
                                      ------------------------------ 
 Novum Securities 
                                      ------------------------------ 
 Corporate Broker 
  Colin Rowbury 
  Jon Belliss                            +44 207 399 9427 
                                      ------------------------------ 
 Tancredi Intelligent Communication 
                                      ------------------------------ 
 Media Relations 
  Helen Humphrey 
  Charlie Hobbs                          +44 744 922 6720 
  cellulargoods@tancredigroup.com        +44 789 755 7112 
                                      ------------------------------

About Cellular Goods PLC:

Cellular Goods develops and markets premium quality skincare and wellness products based on proprietary formulations incorporating biosynthetic lab-made cannabinoids. Our branded products are efficacy-led and research-backed and available online in the UK and US. The Company is incorporated in the UK and listed on the Main Market of the London Stock Exchange. For more information, visit www.cellular-goods.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOEGZGMVNZMGFZM

(END) Dow Jones Newswires

June 12, 2023 13:15 ET (17:15 GMT)

Cellular Goods (LSE:CBX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024 Haga Click aquí para más Gráficas Cellular Goods.
Cellular Goods (LSE:CBX)
Gráfica de Acción Histórica
De May 2023 a May 2024 Haga Click aquí para más Gráficas Cellular Goods.